Hansa Biopharma — Juni 2024
-
Aktierna som hela analytikerkåren gör tummen upp för https://www.borskollen.se/nyheter/27/aktierna-som-hela-analytikerkaren-gor-tummen-upp-for
-
Stadig faldende tendens for shortandelen. https://www.borskollen.se/aktie/hansa-biopharma
-
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.
Yahoo Finance (finance.yahoo.com)
Sarepta stock jumped Thursday after Pfizer's (PFE) rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.
-
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
The failure of another trial adds to uncertainty around the benefits of the gene-based treatments, though industry analysts still expect Sarepta’s Elevidys’ to be unaffected.
BioPharma Dive (www.biopharmadive.com)
-
High-level data fra forsøget forventes i 2024.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind